Non-small cell lung cancer induces an immunosuppressive phenotype of dendritic cells in tumor microenvironment by upregulating B7-H3

Journal of Thoracic Oncology

Volumn 6, Issue 7, 2011, Pages 1162-1168

  Schneider, Thomas ^a   Hoffmann, Hans ^a   Dienemann, Hendrik ^a   Schnabel, Philipp A ^b   Enk, Alexander H ^b   Ring, Sabine ^b   Mahnke, Karsten ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

B7 H3; Dendritic cells; Immunosuppression; Lung cancer; Tumor microenvironment

Indexed keywords

B7 H3 PROTEIN; INTERLEUKIN 10; INTERLEUKIN 12P40; LYMPHOCYTE ANTIGEN; UNCLASSIFIED DRUG;

ARTICLE; CELL ISOLATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE DEFICIENCY; LUNG NON SMALL CELL CANCER; LYMPH NODE; LYMPHOCYTE FUNCTION; MALE; MIXED LYMPHOCYTE REACTION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; TUMOR MICROENVIRONMENT; UPREGULATION;

EID: 79959864289     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31821c421d     Document Type: Article

References (32)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30. (Pubitemid 40310185)
2. O'Mahony D, Kummar S, Gutierrez ME. Non-small-cell lung cancer vaccine therapy: A concise review. J Clin Oncol 2005;23:9022-9028. (Pubitemid 46211486)
3. Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998;4: 328-332. (Pubitemid 28144092)
4. Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 2005;5:296-306. (Pubitemid 40516155)
5. Um SJ, Choi YJ, Shin HJ, et al. Phase I study of autologous dendritic cell tumor vaccine in patients with non-small cell lung cancer. Lung Cancer 2010;70:188-194.
6. Hirschowitz EA, Foody T, Hidalgo GE, et al. Immunization of NSCLC patients with antigen-pulsed immature autologous dendritic cells. Lung Cancer 2007;57:365-372. (Pubitemid 47285427)
7. Bergeron A, El-Hage F, Kambouchner M, et al. Characterisation of dendritic cell subsets in lung cancer micro-environments. Eur Respir J 2006;28:1170-1177. (Pubitemid 44883852)
8. Mahnke K, Johnson TS, Ring S, et al. Tolerogenic dendritic cells and regulatory t cells: A two-way relationship. J Dermatol Sci 2007;46:159-167. (Pubitemid 46601842)
9. Ju S, Qiu H, Zhou X, et al. CD13+CD4+CD25hi regulatory T cells exhibit higher suppressive function and increase with tumor stage in non-small cell lung cancer patients. Cell Cycle 2009;8:2578-2585.
10. Koyama K, Kagamu H, Miura S, et al. Reciprocal CD4+ T-cell balance of effector CD62Llow CD4+ and CD62LhighCD25+ CD4+ regulatory T cells in small cell lung cancer reflects disease stage. Clin Cancer Res 2008;14:6770-6779.
11. Yannelli JR, Tucker JA, Hidalgo G, et al. Characteristics of PBMC obtained from leukapheresis products and tumor biopsies of patients with non-small cell lung cancer. Oncol Rep 2009;22:1459-1471.
12. Zhang Y, Huang S, Gong D, et al. Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer. Cell Mol Immunol 2010;7:389-395.
13. Tabarkiewicz J, Rybojad P, Jablonka A, et al. CD1c+ and CD303+ dendritic cells in peripheral blood, lymph nodes and tumor tissue of patients with non-small cell lung cancer. Oncol Rep 2008;19:237-243. (Pubitemid 351176155)
14. Perrot I, Blanchard D, Freymond N, et al. Dendritic cells infiltrating human non-small cell lung cancer are blocked at immature stage. J Immunol 2007;178:2763-2769. (Pubitemid 46333153)
15. Dumitriu IE, Dunbar DR, Howie SE, et al. Human dendritic cells produce TGF-beta 1 under the influence of lung carcinoma cells and prime the differentiation of CD4+CD25+Foxp3+ regulatory t cells. J Immunol 2009;182:2795-2807.
16. Greenwald RJ, Freeman GJ, Sharpe AH. The b7 family revisited. Annu Rev Immunol 2005;23:515-548. (Pubitemid 40563179)
17. Sobin LH, Gospodarowicz MK, Wittekind C (Ed.), TNM Classification of Malignant Tumors (International Union Against Cancer), 7th ed. New York, NY: Wiley-Blackwell, 2009. Pp. 136-146.
18. Sun M, Richards S, Prasad DV, et al. Characterization of mouse and human B7-H3 genes. J Immunol 2002;168:6294-6297. (Pubitemid 34620050)
19. Chapoval AI, Ni J, Lau JS, et al. B7-H3: A costimulatory molecule for T cell activation and IFN-gamma production. Nat Immunol 2001;2:269-274. (Pubitemid 33706005)
20. Luo L, Chapoval AI, Flies DB, et al. B7-H3 enhances tumor immunity in vivo by costimulating rapid clonal expansion of antigen-specific CD8+ cytolytic T cells. J Immunol 2004;173:5445-5450. (Pubitemid 39392128)
21. Ma L, Luo L, Qiao H, et al. Complete eradication of hepatocellular carcinomas by combined vasostatin gene therapy and B7H3-mediated immunotherapy. J Hepatol 2007;46:98-106. (Pubitemid 44827415)
22. Lupu CM, Eisenbach C, Kuefner, et al. An orthotopic colon cancer model for studying the B7-H3 antitumor effect in vivo. J Gastrointest Surg 2006;10:635-645. (Pubitemid 43711146)
23. Loos M, Hedderich DM, Ottenhausen M, et al. Expression of the costimulatory molecule B7-H3 is associated with prolonged survival in human pancreatic cancer. BMC Cancer 2009;9:463.
24. Yamato I, Sho M, Nomi T, et al. Clinical importance of B7-H3 expression in human pancreatic cancer. Br J Cancer 2009;101:1709-1716.
25. Hashiguchi M, Kobori H, Ritprajak P, et al. Triggering receptor expressed on myeloid cell-like transcript 2 (TLT-2) is a counter-receptor for B7-H3 and enhances T cell responses. Proc Natl Acad Sci USA 2008;105:10495-10500.
26. Suh WK, Gajewska BU, Okada H, et al. The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses. Nat Immunol 2003;4:899-906. (Pubitemid 37098661)
27. Prasad DV, Nguyen T, Li Z, et al. Murine B7-H3 is a negative regulator of T cells. J Immunol 2004;173:2500-2506. (Pubitemid 39063108)
28. Crispen PL, Sheinin Y, Roth TJ, et al. Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma. Clin Cancer Res 2008;14:5150-5157.
29. Hofmeyer KA, Ray A, Zang X. The contrasting role of B7-H3. Proc Natl Acad Sci USA 2008;105:10277-10278.
30. Yi KH, Chen L. Fine tuning the immune response through B7-H3 and B7-H4. Immunol Rev 2009;229:145-151.
31. Sun Y, Wang Y, Zhao J, et al. B7-H3 and B7-H4 expression in non-small-cell lung cancer. Lung Cancer 2006;53:143-151. (Pubitemid 43994236)
32. Zhang R, Shao F, Wu X, et al. Value of quantitative analysis of circulating cell free DNA as a screening tool for lung cancer: A metaanalysis. Lung Cancer 2009;69:225-231.